Pages that link to "Q58586406"

The following pages link to Lotte Bjerre Knudsen (Q58586406):

Displaying 50 items.

• Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus (Q26749191) (← links)
• Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor (Q27657999) (← links)
• Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide (Q27701894) (← links)
• Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus (Q28201902) (← links)
• Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration (Q28378259) (← links)
• The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss (Q30596646) (← links)
• Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. (Q30873914) (← links)
• Identification of alkylidene hydrazides as glucagon receptor antagonists. (Q31968630) (← links)
• New beta-alanine derivatives are orally available glucagon receptor antagonists (Q33268069) (← links)
• The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist (Q34104467) (← links)
• Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. (Q34745109) (← links)
• Small-molecule agonists for the glucagon-like peptide 1 receptor (Q35612392) (← links)
• Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats (Q35757217) (← links)
• GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. (Q35762689) (← links)
• Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. (Q35855868) (← links)
• The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. (Q35902899) (← links)
• Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease (Q36078803) (← links)
• Expression of the GLP-1 receptor in mouse, rat, and human pancreas (Q36838681) (← links)
• Liraglutide: the therapeutic promise from animal models. (Q37795871) (← links)
• Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor. (Q38288238) (← links)
• The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice (Q38363214) (← links)
• Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes. (Q39017198) (← links)
• GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. (Q39030156) (← links)
• Functional importance of GLP-1 receptor species and expression levels in cell lines. (Q39411043) (← links)
• GLP-1 Induces Barrier Protective Expression in Brunner's Glands and Regulates Colonic Inflammation. (Q39473017) (← links)
• A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model. (Q39544576) (← links)
• Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. (Q39732229) (← links)
• A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules (Q39896648) (← links)
• Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness (Q40058795) (← links)
• Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists. (Q40987578) (← links)
• GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics (Q41861947) (← links)
• The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease. (Q42125458) (← links)
• Comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125. (Q42874262) (← links)
• Comment on Andersen et al, pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop (Q42956799) (← links)
• Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome. (Q43052220) (← links)
• Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus (Q43224245) (← links)
• Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture (Q43263229) (← links)
• Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. (Q43349026) (← links)
• Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties. (Q43471607) (← links)
• Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice. (Q43669824) (← links)
• Human glucagon receptor antagonists based on alkylidene hydrazides (Q43886234) (← links)
• NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs (Q44136587) (← links)
• The glucagon-like peptide-1 receptor--or not? (Q44489452) (← links)
• Development of a cysteine-deprived and C-terminally truncated GLP-1 receptor. (Q45264326) (← links)
• Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide. (Q46170683) (← links)
• The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro (Q46409597) (← links)
• The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. (Q46519391) (← links)
• Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats. (Q46707968) (← links)
• Characterization of the glucagon-like peptide-1 receptor in male mouse brain using a novel antibody and in situ hybridization. (Q47228121) (← links)
• Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. (Q47308234) (← links)